Cipla reported Q2 FY27 net profit of ₹4,374 Cr on revenue of ₹23,845 Cr, with profit up +30.8% year-on-year and short of street estimates. The stock fell in reaction as investors weighed the margin trend and management's outlook for the rest of the year.
Last 8 quarters / 3 years
| Period | Revenue | Net Profit | EPS | YoY | QoQ |
|---|---|---|---|---|---|
| Q3 FY25 | ₹19,004 Cr | ₹2,860 Cr | ₹35.34 | — | — |
| Q4 FY25 | ₹20,696 Cr | ₹3,615 Cr | ₹44.67 | — | +26.4% |
| Q1 FY26 | ₹22,236 Cr | ₹4,167 Cr | ₹51.49 | — | +15.3% |
| Q2 FY26 | ₹22,220 Cr | ₹3,345 Cr | ₹41.34 | — | -19.7% |
| Q3 FY26 | ₹22,590 Cr | ₹4,513 Cr | ₹55.77 | +57.8% | +34.9% |
| Q4 FY26 | ₹22,405 Cr | ₹3,898 Cr | ₹48.17 | +7.8% | -13.6% |
| Q1 FY27 | ₹22,566 Cr | ₹3,842 Cr | ₹47.48 | -7.8% | -1.4% |
| Q2 FY27 | ₹23,845 Cr | ₹4,374 Cr | ₹54.05 | +30.8% | +13.9% |
Last 4 quarters
In an exchange filing, Cipla said its board cleared a multi-year investment to expand capacity, aimed at meeting demand and improving operating leverage over the medium term.
Several brokerages maintained a positive stance on Cipla, citing improving return ratios and a clearer growth runway, while a few flagged valuations as the key risk.
Cipla reported revenue and profit broadly in line with Street expectations, with management flagging stable demand and a healthy order pipeline into the second half.
Cipla entered a strategic partnership to widen its addressable market. Management expects the tie-up to contribute modestly to revenue over the next few quarters.
Tap a metric label to learn what it means.
Pharmaceuticals
| Company | P/E | 1Y |
|---|---|---|
| Sun Pharmaceutical ₹4,27,000 Cr | 48.5 | +36.2% |
| Dr. Reddy's Laboratories ₹1,07,000 Cr | 50.3 | +6.6% |
| Divi's Laboratories ₹1,57,000 Cr | 39.8 | +7.0% |
| Apollo Hospitals ₹99,000 Cr | 40.8 | +25.2% |
Cipla is a leading Indian company in the pharmaceuticals space within the Healthcare sector. It is a constituent of the Nifty 50 and is actively tracked by institutional and retail investors.